share_log

TransCode Therapeutics analyst ratings

Benzinga Analyst Ratings ·  Jun 7, 2022 06:24
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
06/07/2022 468.18% HC Wainwright & Co. → $10 Initiates Coverage On → Buy

TransCode Therapeutics Questions & Answers

What is the target price for TransCode Therapeutics (RNAZ)?

The latest price target for TransCode Therapeutics (NASDAQ: RNAZ) was reported by HC Wainwright & Co. on June 7, 2022. The analyst firm set a price target for $10.00 expecting RNAZ to rise to within 12 months (a possible 468.18% upside). 1 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for TransCode Therapeutics (RNAZ)?

The latest analyst rating for TransCode Therapeutics (NASDAQ: RNAZ) was provided by HC Wainwright & Co., and TransCode Therapeutics initiated their buy rating.

When is the next analyst rating going to be posted or updated for TransCode Therapeutics (RNAZ)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransCode Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransCode Therapeutics was filed on June 7, 2022 so you should expect the next rating to be made available sometime around June 7, 2023.

Is the Analyst Rating TransCode Therapeutics (RNAZ) correct?

While ratings are subjective and will change, the latest TransCode Therapeutics (RNAZ) rating was a initiated with a price target of $0.00 to $10.00. The current price TransCode Therapeutics (RNAZ) is trading at is $1.76, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment